AU2011206761A1 - Anti - infective pyrido (1,2 -a) pyrimidines - Google Patents

Anti - infective pyrido (1,2 -a) pyrimidines Download PDF

Info

Publication number
AU2011206761A1
AU2011206761A1 AU2011206761A AU2011206761A AU2011206761A1 AU 2011206761 A1 AU2011206761 A1 AU 2011206761A1 AU 2011206761 A AU2011206761 A AU 2011206761A AU 2011206761 A AU2011206761 A AU 2011206761A AU 2011206761 A1 AU2011206761 A1 AU 2011206761A1
Authority
AU
Australia
Prior art keywords
nmr
mhz
pyrido
heteroaryl
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011206761A
Other languages
English (en)
Other versions
AU2011206761A2 (en
Inventor
Priscille Brodin
Jonathan Cechetto
Thierry Christophe
Monica Contreras Dominguez
Fanny Anne Ewann
Denis Philippe Cedric Fenistein
Auguste Genovesio
Jamung Heo
Heekyoung Jeon
Sunhee Kang
Eunhye Kim
Jaeseung Kim
Saeyeon Lee
Ji Youn Nam
Zaesung No
Eunjung Park
Min Jung Seo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur Korea
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur Korea filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of AU2011206761A1 publication Critical patent/AU2011206761A1/en
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR KOREA reassignment INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) Amend patent request/document other than specification (104) Assignors: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (EPST), INSTITUT PASTEUR KOREA
Publication of AU2011206761A2 publication Critical patent/AU2011206761A2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2011206761A 2010-01-13 2011-01-13 Anti - infective pyrido (1,2 -a) pyrimidines Abandoned AU2011206761A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29455210P 2010-01-13 2010-01-13
US61/294,552 2010-01-13
PCT/EP2011/000135 WO2011085990A1 (en) 2010-01-13 2011-01-13 Anti - infective pyrido (1,2 -a) pyrimidines

Publications (2)

Publication Number Publication Date
AU2011206761A1 true AU2011206761A1 (en) 2012-07-12
AU2011206761A2 AU2011206761A2 (en) 2012-12-13

Family

ID=43610218

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011206761A Abandoned AU2011206761A1 (en) 2010-01-13 2011-01-13 Anti - infective pyrido (1,2 -a) pyrimidines

Country Status (9)

Country Link
US (1) US20130012506A1 (pt-PT)
EP (1) EP2523956A1 (pt-PT)
JP (1) JP2013517233A (pt-PT)
KR (1) KR20130088002A (pt-PT)
CN (1) CN102812023A (pt-PT)
AU (1) AU2011206761A1 (pt-PT)
BR (1) BR112012017473A2 (pt-PT)
CA (1) CA2786329A1 (pt-PT)
WO (1) WO2011085990A1 (pt-PT)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014019750B1 (pt) * 2012-02-10 2020-03-03 F. Hoffmann-La Roche Ag. Composto, composição farmacêutica e seus usos
JP6092264B2 (ja) 2012-03-01 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋委縮症を処置するための化合物
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
EP3227292B1 (en) * 2014-12-02 2022-03-09 Alterity Therapeutics Limited 4H-PYRIDO[1,2-a]PYRIMIDIN-4-ONE COMPOUNDS
US10668171B2 (en) 2015-05-30 2020-06-02 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
CN105153151A (zh) * 2015-08-28 2015-12-16 张文莲 一种嘧啶酮类化合物的合成方法
WO2017100726A1 (en) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
EP3544435A4 (en) 2016-11-28 2020-11-04 PTC Therapeutics, Inc. RNA SPLICE MODULATION PROCESSES
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2018232039A1 (en) 2017-06-14 2018-12-20 Ptc Therapeutics, Inc. Methods for modifying rna splicing
CA3067592A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
WO2019005980A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
SG11202009212WA (en) 2018-03-27 2020-10-29 Ptc Therapeutics Inc Compounds for treating huntington's disease
EP3814360A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210042265A (ko) 2018-06-27 2021-04-19 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로사이클릭 및 헤테로아릴 화합물
CN114106000B (zh) * 2021-12-15 2023-11-24 中国科学院新疆理化技术研究所 一种咪唑并[4,5-d]嘧啶酮三环类衍生物及抗肿瘤用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO2001058876A1 (fr) * 2000-02-09 2001-08-16 Daiichi Pharmaceutical Co., Ltd. Agents antibacteriens acidoresistants renfermant des acides pyridonecarboxyliques comme principe actif
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN102105470B (zh) * 2008-06-17 2014-06-04 韩国巴斯德研究所 作为抗结核病药的吡啶并嘧啶化合物
WO2010001366A1 (en) * 2008-07-04 2010-01-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Piperazines derivatives as proteasome modulators

Also Published As

Publication number Publication date
CA2786329A1 (en) 2011-07-21
WO2011085990A8 (en) 2012-10-26
WO2011085990A1 (en) 2011-07-21
KR20130088002A (ko) 2013-08-07
CN102812023A (zh) 2012-12-05
EP2523956A1 (en) 2012-11-21
US20130012506A1 (en) 2013-01-10
JP2013517233A (ja) 2013-05-16
BR112012017473A2 (pt) 2019-09-24
AU2011206761A2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
AU2011206761A1 (en) Anti - infective pyrido (1,2 -a) pyrimidines
AU2009267519B2 (en) Pyridopyrimidine compounds as anti-tubercular agents
KR101732212B1 (ko) 항감염성 화합물
JP6215338B2 (ja) キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
US20090156578A1 (en) 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
JP3110765B2 (ja) ピリド［２，３−ｄ］ピリミジン誘導体及びその医薬組成物
WO2007053131A2 (en) Acrylamide derivatives as antibiotic agents
CA3204171A1 (en) Bicyclic derivatives
JP2006517976A (ja) 新規化合物
JP2019509272A (ja) 脊髄性筋萎縮症の治療のための併用療法
WO2019063748A1 (en) INHIBITORS OF ROR-GAMMA
AU2006228142A1 (en) Imidazopyridine derivatives useful as iNOS inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 JUL 2012

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application